Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov 2;28(11):921-924.
doi: 10.1093/oncolo/oyad256.

Waiting for ASCO to "Walk the Walk"

Tito Fojo  1
Affiliations
Editorial

Waiting for ASCO to "Walk the Walk"

Tito Fojo. Oncologist. .

Abstract

This editorial addresses the magnitude of the challenge of spiraling drug costs, a challenge that affects everyone, everywhere, but may not be adequately addressed even at the ASCO annual meeting.

PubMed Disclaimer

Conflict of interest statement

The author indicated no financial relationships.

Comment on

  • Highlights of ASCO 2023.
    Neugut AI, Bates SE. Neugut AI, et al. Oncologist. 2023 Sep 7;28(9):739-742. doi: 10.1093/oncolo/oyad222. Oncologist. 2023. PMID: 37548435 Free PMC article.

References

    1. Neugut AI, Bates SE.. Highlights of ASCO 2023. The Oncologist, 2023;28(9):739-742. 10.1093/oncolo/oyad222 - DOI - PMC - PubMed
    1. Herbst RS, Tsuboi M, John T, et al. . Overall survival analysis from the ADAURA trial of adjuvant simertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2023;41(17_suppl):LBA3-LBA3. 10.1200/jco.2023.41.17_suppl.lba3 - DOI
    1. Yue D, Xu S, Wang Q, et al. . Updated overall survival and exploratory analysis from randomized, phase II EVAN study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in stage IIIA epidermal growth factor receptor+ non-small-cell lung cancer. J Clin Oncol. 2022;40(34):3912-3917. 10.1200/JCO.22.00428 - DOI - PubMed
    1. Zhong W-Z, Wang Q, Mao W-M, et al. . Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol. 2021;39(7):713-722. 10.1200/JCO.20.01820 - DOI - PMC - PubMed
    1. Tada H, Mitsudomi T, Misumi T, et al. . Randomized phase III study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage II-IIIA non-small-cell lung canbcer with EGFR mutation (IMPACT). J Clin Oncol. 2022;40(3):231-241. - PubMed